Merck (MRK) Tops Q1 EPS by 17c, Updates FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Merck Announces First-Quarter 2019 Financial Results
April 30, 2019 6:45 AM EDTFirst-Quarter 2019 Worldwide Sales Were $10.8 Billion, an Increase of 8%; Sales Increased 11% Excluding Negative Impact from Foreign Exchange; Growth Driven by Oncology and Vaccines Sales in China Were $725 Million in the First Quarter, an Increase of 58%; Sales in China Increased 67% Excluding Negative Impact from Foreign Exchange Strong GAAP and Non-GAAP EPS Growth for First-Quarter 2019 GAAP EPS Was $1.12 in First-Quarter 2019 Versus $0.27 in First-Quarter 2018, which Included a Charge of $1.4 Billion Related to the Formation of a Collaboration with Eisai Co., Ltd. Non-GAAP EPS Was $1.22 in First-Quarter 2019 Versus $1.05 in First-Quarter 2018... More
